This week on Capitol Hill, the heated drug pricing debate is back in the spotlight, with a Senate Judiciary Committee hearing on intellectual property and the price of prescription drugs on Tuesday. In the House of Representatives, oversight hearings will examine both the activities of the U.S. Patent and Trademark Office and data security efforts made by the Federal Trade Commission. Off the Hill, The Cato Institute looks at U.S. cyber defense capabilities, and the week closes with a Brookings Institution event on China’s actions towards global tech dominance.
Patent
- Enablement
- Fee Shifting
- Litigation
- COVID IP Waiver Attempts are Becoming Harder to Justify
- Coons and Hirono Raise Concerns Over Pride in Patent Ownership Act Penalties
- The Fintiv Deception: Leahy’s Legislative ‘Fix’ is Unwarranted in Light of Sotera Wireless
- An Ax(le) Needs Grinding: Can the Federal Circuit Turn the Wheel?
- India’s Prius Judgment and Trans-Border Reputation of Trademarks
Recent Posts
- COVID IP Waiver Attempts are Becoming Harder to Justify
- Coons and Hirono Raise Concerns Over Pride in Patent Ownership Act Penalties
- The Fintiv Deception: Leahy’s Legislative ‘Fix’ is Unwarranted in Light of Sotera Wireless
- An Ax(le) Needs Grinding: Can the Federal Circuit Turn the Wheel?
- India’s Prius Judgment and Trans-Border Reputation of Trademarks